J&J's Single Dose COVID-19 Vaccine Candidate Shows Robust Protection In Pre-clinical Studies

(RTTNews) - Healthcare company Johnson & Johnson (JNJ) announced Thursday that its lead vaccine candidate protected against infection with SARS-CoV-2, the virus that causes COVID-19, with a single dose in pre-clinical studies.

The data, published in Nature, show the Company's investigational adenovirus serotype 26 (Ad26) vector-based vaccine elicited a robust immune response as demonstrated by "neutralizing antibodies," successfully preventing subsequent infection and providing complete or near-complete protection in the lungs from the virus in non-human primates (NHPs) in the pre-clinical study.

Based on the strength of the data, a Phase 1/2a first-in-human clinical trial of the vaccine candidate, Ad26.COV2.S, in healthy volunteers, has now commenced in the United States and Belgium.

The robust Janssen COVID-19 clinical trial program, including the Phase 1/2a clinical trial and the Phase 3 clinical trial program, will evaluate both one- and two-dose regimens of Ad26.COV2.S in parallel studies.